Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

By afschroeder • October 25, 2025

Lane AA, Papayannidis C, Angelucci E, McCloskey J, Schiller GJ, de la Fuente Burguera A, Montesinos P, Nagarwala Y, Herling M, Mannis G, Pemmaraju N. Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma. 2025 Oct 24:1-9. doi: 10.1080/10428194.2025.2557505. Epub ahead of print. PMID: 41134616.

Tags: Adverse effects, Blastic plasmacytoid dendritic cell neoplasm, capillary leak syndrome, Hematology/Oncology, Monitoring, Publications, symptom management, tagraxofusp

Related Posts

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]